Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

INVO Fertility (IVF) EBITDA (2016 - 2025)

INVO Fertility (IVF) has disclosed EBITDA for 15 consecutive years, with $14.3 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA rose 911.17% to $14.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$3.0 million, a 55.0% increase, with the full-year FY2024 number at -$1.8 million, up 72.96% from a year prior.
  • EBITDA was $14.3 million for Q3 2025 at INVO Fertility, up from -$3.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $14.3 million in Q3 2025 to a low of -$17.1 million in Q1 2025.
  • A 5-year average of -$1.6 million and a median of -$1.9 million in 2021 define the central range for EBITDA.
  • Biggest YoY gain for EBITDA was 911.17% in 2025; the steepest drop was 1049.64% in 2025.
  • INVO Fertility's EBITDA stood at $514987.0 in 2021, then plummeted by 624.06% to -$2.7 million in 2022, then skyrocketed by 44.89% to -$1.5 million in 2023, then soared by 286.81% to $2.8 million in 2024, then skyrocketed by 414.77% to $14.3 million in 2025.
  • Per Business Quant, the three most recent readings for IVF's EBITDA are $14.3 million (Q3 2025), -$3.0 million (Q2 2025), and -$17.1 million (Q1 2025).